The twist in this little medical thriller is that the witness was in the bathroom the whole time. Not the CT scanner. Not the biopsy needle. Not some glowing sci-fi pod humming in a billionaire bunker. Urine. Plain, boring, aggressively unglamorous urine.
A new 2026 study in npj Precision Oncology asked a wild but very sensible question: could a urine sample help spot lung cancer early, and maybe even hint whether the cancer is coming back later on? Turns out the answer might be yes, which is both exciting and a bit rude. Your bladder was apparently keeping tabs.
Tiny molecular gossip, delivered in bubble wrap
The stars of this story are microRNAs, or miRNAs. These are tiny bits of RNA that help control which proteins cells make. Think of them as molecular dimmer switches, except the wiring diagram was written by someone who clearly enjoyed chaos.
Cancer cells often have weird miRNA patterns. They also shed little membrane bubbles called extracellular vesicles, which are basically microscopic padded envelopes stuffed with biological gossip. Those vesicles can end up in body fluids, including urine. So if a lung tumor is leaving fingerprints in those vesicles, a urine test might catch them without anyone having to stick a needle into your chest. Huge upgrade. Needles remain very committed to ruining everyone’s day.
What the researchers actually did
The team analyzed urine from 278 people with lung cancer and 213 people without cancer. About half of the cancer group had early-stage disease, which is the part clinicians care about most for detection, because finding cancer early is the difference between “annoying medical problem” and “plotline nobody wanted.”
They used small RNA sequencing to read the urinary extracellular-vesicle miRNAs, then trained a machine-learning model to tell cancer from non-cancer. The results were strong for a case-control study: the model had an AUC of 0.942 in the training set and 0.941 in the test set. For early-stage lung cancer, sensitivity and specificity were 82.0% and 92.5% in training, then 88.2% and 87.0% in testing.[1]
That matters because lung cancer screening still leans on low-dose CT scans, which save lives but come with practical headaches: who gets screened, what to do with suspicious nodules, how to deal with false alarms, and how to make the whole process less like an obstacle course built by insurance paperwork.[2-4]
This urine test is not ready to replace CT. Not even close. But it could become a useful sidekick. Batman still needs Batman, but Robin can definitely help narrow the suspect list.
The part that gets really interesting
The paper did not stop at early detection. The researchers also found 12 miRNAs that dropped after surgery and rose again when cancer recurred. That is a big deal conceptually. It suggests the test might not just say, “Hey, something looks off.” It might also help track whether treatment worked and whether the cancer is sneaking back in through the side door wearing sunglasses.
They also identified 11 miRNAs linked to recurrence-free survival and built a 3-miRNA prognostic panel that separated patients into higher-risk and lower-risk groups.[1] In plain English: the same kind of urine sample might one day help doctors estimate who needs closer follow-up after surgery. That is the oncology version of finding out which smoke alarm batteries are actually worth trusting at 2 a.m.
And this idea does not come out of nowhere. Other recent work has shown that circulating and extracellular-vesicle miRNAs can carry useful lung-cancer signals for diagnosis, prognosis, and treatment monitoring.[2,5] Reviews over the last few years have basically been saying the same thing with more syllables: liquid biopsy is promising, miRNAs are interesting, and biology refuses to make anything simple.[2-4]
Before we start throwing a parade for the toilet
A few caution lights are blinking, and they should be. This was a case-control study, which is a good way to develop a test but not the same as proving it works in real-world screening. The study authors also noted differences between groups such as age and sample storage, which can muddy biomarker results.[1] And with miRNA assays generally, researchers still wrestle with standardization, reproducibility, and what happens when a “promising signal” meets the messy reality of everyday clinics.[2-4]
So no, this is not “pee in a cup, solve lung cancer by Friday.” Science rarely moves that neatly. Science is more like assembling IKEA furniture with missing screws and a Latin glossary.
Still, the big idea here is genuinely compelling: a noninvasive urine test that helps catch lung cancer earlier, flags recurrence, and gives doctors another tool besides imaging alone. If that holds up in larger, prospective studies, it could make screening and follow-up easier, faster, and less invasive for a disease that desperately needs better early-warning systems.
Which brings us back to the thriller ending. The clue was there all along. In the bathroom. Quietly minding its own business. Frankly, it deserves a better agent.
References
-
Kiritani A, Mori S, Nojiri T, et al. A noninvasive urinary microRNA-based assay for early detection of lung cancer and its potential application to prognosis and recurrence monitoring: a case-control study. npj Precision Oncology. 2026. DOI: https://doi.org/10.1038/s41698-026-01418-w
-
Rosell R, Santarpia M, Pedraz-Valdunciel C, et al. Liquid biopsy in detecting early non-small cell lung cancer. Journal of Liquid Biopsy. 2023;1:100001. DOI: https://doi.org/10.1016/j.jlb.2023.100001 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11863710/
-
Zhu W, Love K, Gray SW, Raz DJ. Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions. Clinical Lung Cancer. 2023;24(3):209-217. DOI: https://doi.org/10.1016/j.cllc.2023.01.006
-
Wan JCM, Sasieni P, Rosenfeld N. Promises and pitfalls of multi-cancer early detection using liquid biopsy tests. Nature Reviews Clinical Oncology. 2025;22:566-580. DOI: https://doi.org/10.1038/s41571-025-01033-x
-
Abdipourbozorgbaghi M, Vancura A, Radpour R, Haefliger S. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC). British Journal of Cancer. 2024;131:1350-1362. DOI: https://doi.org/10.1038/s41416-024-02831-3
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.